Our manufacturing facility is up to par with GMP standards. We are currently working on technologies that can be used in the early diagnosis of Parkinson’s disease and diabetes mellitus.

GMP (Good Manufacturing Practice)

GMP (Good Manufacturing Practice) is a system that regulates the guidelines. PeopleBio’s GMP facility was established in 2016 and acquired ISO 13485:2016 in 2020.


2019 2020 2021 2022 2023 2024
MDS-α Synuclein
(Parkinson's disease)
Basic Research Proof of concept SOP Prototype Clinical Trial & Approval Launching & Sales
Basic Research Proof of concept SOP Prototype Clinical Trial & Approval Launching & Sales
The 3 main
geriatric illnesses
Parkinson's disease

Parkinson's disease

Parkinson’s disease is one of the three main geriatric illnesses along with dementia and stroke, whose prevalence has spiked along with the general aging of the global population. It is a neurodegenerative disease that is characterized by motor disturbances such as tremors, stiffness of muscles, and slow movement. Lack of intervention at an earlier stage may be followed by the complete loss of independent life caused by the progressive dysfunction of motor abilities. It is believed that the abnormal aggregation of α-synuclein, a protein that is the main component of lewy bodies, is the main biomarker of Parkinson’s Disease. At PeopleBio, we are working on a blood-based diagnostic kit that enables the early diagnosis of Parkinson’s Disease through the detection of α-synuclein using our MDS platform technology.


Diabetes is a metabolic disease caused by low levels of insulin or the dysfunction of the pancreas. Amylin is the protein that is secreted along with insulin from the beta cells of the pancreas to regulate blood sugar levels, which is responsible for the rate of glucose. Diabetes develops when amylin aggregates and destroys the beta cells. PeopleBio is currently conducting research towards the development of a diagnostic technology based on MDS that would enable the detection of amylin from blood.